Pro Medicus Ltd
ASX:PME

Watchlist Manager
Pro Medicus Ltd Logo
Pro Medicus Ltd
ASX:PME
Watchlist
Price: 248.65 AUD -0.63% Market Closed
Market Cap: 26B AUD
Have any thoughts about
Pro Medicus Ltd?
Write Note

Pro Medicus Ltd
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pro Medicus Ltd
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
Pro Medicus Ltd
ASX:PME
Common Shares Outstanding
AU$104.4m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
4DMedical Ltd
ASX:4DX
Common Shares Outstanding
AU$410.4m
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
N/A
CogState Ltd
ASX:CGS
Common Shares Outstanding
$170.8m
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
6%
Medibio Ltd
ASX:MEB
Common Shares Outstanding
AU$4.5B
CAGR 3-Years
59%
CAGR 5-Years
83%
CAGR 10-Years
N/A
Medadvisor Ltd
ASX:MDR
Common Shares Outstanding
AU$550.5m
CAGR 3-Years
13%
CAGR 5-Years
N/A
CAGR 10-Years
22%
Alcidion Group Ltd
ASX:ALC
Common Shares Outstanding
AU$1.3B
CAGR 3-Years
8%
CAGR 5-Years
10%
CAGR 10-Years
26%
No Stocks Found

Pro Medicus Ltd
Glance View

Market Cap
26B AUD
Industry
Health Care
Economic Moat
Wide

Pro Medicus Ltd, an Australian company founded in 1983, has etched its name in the field of healthcare IT, primarily through its innovative medical imaging software solutions. The brainchild of Dr. Sam Hupert and Anthony Hall, the company originally sought to provide radiology practices with digital solutions for image management and viewing. Over the years, Pro Medicus has meticulously evolved its offerings to become a leader in picture archiving and communication systems (PACS), radiology information systems (RIS), and an expanding range of e-health solutions. Its flagship product, Visage 7, is renowned for delivering fast and sophisticated viewing capabilities, enabling radiologists to efficiently interpret complex imaging data. Under its hood, the company’s technology is powered by advanced streaming capabilities, allowing for large files to be quickly accessed and reviewed, essential for high-demand environments. The monetization model of Pro Medicus largely revolves around licensing agreements for its software, alongside service and support fees, ensuring a steady and recurring revenue stream. The company has successfully leveraged its expertise to penetrate key markets, notably the United States and Europe, where it partners with some of the most prestigious hospitals and research institutions. By focusing on high-end offerings and fostering long-term client relationships, Pro Medicus has cemented a premium positioning in the healthcare IT landscape. The strategic focus on innovation, coupled with a keen understanding of the evolving needs of healthcare providers, allows Pro Medicus to continually refine its services, ensuring it remains at the forefront of technological advancements that ultimately enhance diagnostic efficiency and patient outcomes.

PME Intrinsic Value
30.32 AUD
Overvaluation 88%
Intrinsic Value
Price

See Also

What is Pro Medicus Ltd's Common Shares Outstanding?
Common Shares Outstanding
104.4m AUD

Based on the financial report for Jun 30, 2024, Pro Medicus Ltd's Common Shares Outstanding amounts to 104.4m AUD.

What is Pro Medicus Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
0%

Over the last year, the Common Shares Outstanding growth was 0%.

Back to Top